Tolvaptan (SAMSCA) ( DrugBank: Tolvaptan )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 72 | Pituitary ADH secretion disorder | 1 |
72. Pituitary ADH secretion disorder
Clinical trials : 41 / Drugs : 27 - (DrugBank : 8) / Drug target genes : 7 - Drug target pathways : 10
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04790175 (ClinicalTrials.gov) | March 29, 2021 | 25/2/2021 | Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH | Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in Japan | Antidiuretic Hormone, Inappropriate Secretion | Drug: Tolvaptan (SAMSCA) | Otsuka Pharmaceutical Co., Ltd. | NULL | Recruiting | N/A | N/A | All | 300 | Japan |